Management of hypertension during lenvatinib for advanced thyroid cancer: a suggested diagnostic and therapeutic algorithm
Authors' conclusion
HTN is a frequent and early AE in patients on LEN treatment. We suggest a diagnostic and therapeutic algorithm to be applied in clinical practice to allow efficient HTN control and improve patient compliance, reducing LEN discontinuation.
Study context
- Population
- Consecutive patients treated with lenvatinib for advanced thyroid cancer, single tertiary-care centre
- Participants
- 29 patients
- Outcome
- Incidence, features and best management of LEN-related hypertension
Methodological detailssingle tertiary-care centre, consecutive cohort, Mean follow-up 29.8 months (6-77 months)
- Single tertiary-care centre
- Consecutive cohort
- Mean follow-up 29.8 months (6-77 months)
Main finding
As reported in the abstract
Incidence of HTN during LEN · mean follow-up 6.8 months
- Hypertension (HTN) recorded
- 76% of cases
- De novo HTN
- half of them
- HTN grade 1, grade 2 and grade 3
- 5%, 50% and 45% of patients, respectively
Observational data: associations, not effects.
Further findings
Correlates of hypertension
- No correlation between hypertension and proteinuria, clinical features, best morphological response or any other adverse event (AE), except diarrhoea
- Similar incidence of hypertension with or without pre-existing hypertension or other CVD
Safety
- Patients with hypertension who developed proteinuria
- 77%
Original publication
Management of hypertension during lenvatinib for advanced thyroid cancer: a suggested diagnostic and therapeutic algorithm. Eur Thyroid J. Published 21 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →